Terifrac Injection is used to treat severe osteoporosis in postmenopausal women and men at high risk of fractures, helping to build new bone and reduce fracture risk.
It contains teriparatide (750 mcg/3 mL), a parathyroid hormone analogue. It is given as a daily subcutaneous injection, usually in the thigh or abdomen. Treatment is limited to a maximum of 24 months in a lifetime.
Adequate calcium and vitamin D intake as directed, and regular bone density monitoring, support safe treatment alongside this medicine.
Tell your doctor about any Paget's disease of bone, previous bone radiation, raised calcium levels or bone cancer before starting. Sit down for the first few injections in case of dizziness on standing. Report new or unusual bone pain, swelling or a lump at the injection site.



































































